ADPT President and COO Julie Rubinstein Sells $314K of Stock

Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation (ADPT), sold 11,881 shares on October 9, 2026, for a total value of $313,777.21. The sale was planned, reflecting her ongoing trading activity in the company’s shares.

Inside Julie Rubinstein's Trade

Rubinstein executed the sale at an average price of $26.41 per share. This transaction marks her latest move in a pattern of trading activity, as she continues to adjust her holdings in the company.

Other Institutional Activity in Adaptive Biotechnologies

Viking Global Investors, L.P. holds 29,993,708 shares, while BlackRock Inc. increased its stake by 1,835,856 shares, bringing its total to 15,139,159 shares valued at about $363.6 million. Vanguard Capital Management LLC also added 309,576 shares, bringing its total to 6,403,587 shares worth approximately $153.8 million. Wellington Management Group, LLP grew its holdings by 2,054,031 shares, resulting in a total of 5,911,366 shares valued at about $142.0 million, and Vanguard Portfolio Management LLC increased its stake by 984,940 shares, totaling 5,476,231 shares worth about $131.5 million.

Adaptive Biotechnologies Corporation Stock Down 5.4%

Adaptive Biotechnologies' stock recently traded around $24.19 as of October 16, 2026. This price is below its 50-day moving average of $26.17, indicating a potential challenge for upward momentum. The stock is also about 21.3% below its 52-week high of $30.74, reflecting some volatility in its recent performance.

Recent Earnings

For the trailing twelve months, Adaptive Biotechnologies reported revenue of $308.1 million, but it has a negative net margin of -20.7% and a return on equity of -38.8%. The next earnings report is expected on November 4, 2026.

Insider Buying and Selling at Adaptive Biotechnologies Corporation

On June 25, 2026, Chief Commercial Officer Susan Bobulsky sold 5,000 shares at $20.50, worth $102,500. Additionally, Griffin Michelle Renee sold 52,084 shares at $20.18, totaling over $1 million. Sharon Benzeno also sold 11,034 shares for $231,714 on June 26, 2026. Earlier, on June 29, Benzeno made a significant purchase, acquiring over 103,000 shares valued at about $751,605.

Analysts Set New Price Targets

On July 30, 2026, Morgan Stanley maintained its 'Equal-Weight' rating with a price target of $22.0. Piper Sandler also maintained its 'Overweight' rating with a target of $27.5 on August 4, 2026. BTIG maintained a 'Buy' rating with a target of $34.0 on September 22, 2026, while Goldman Sachs initiated coverage with a 'Buy' rating and a target of $35.0 on September 29, 2026. Guggenheim maintained a 'Buy' rating with a target of $32.0 on October 1, 2026. The consensus recommendation is a 'strong buy' with a mean price target of $29.81 from eight analysts.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation develops a platform for immune medicine, focusing on diagnosing and treating various diseases. The company utilizes advanced technology to analyze the adaptive immune system, aiming to improve patient outcomes.

Bottom Line

Investors should watch for the upcoming earnings report on November 4, 2026, for updates on the company's financial health. Additionally, keep an eye on any further insider trading activity as it may signal management's confidence in the company.